Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, Heymach JV, Weinstein JN, Coombes KR, Wang J, Byers LA. Mak MP, et al. Among authors: william wn. Clin Cancer Res. 2016 Feb 1;22(3):609-20. doi: 10.1158/1078-0432.CCR-15-0876. Epub 2015 Sep 29. Clin Cancer Res. 2016. PMID: 26420858 Free PMC article.
Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Papadimitrakopoulou VA, William WN Jr, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CO, Helman JI, Du B, Yueh B, Boyle JO. Papadimitrakopoulou VA, et al. Among authors: william wn jr. Clin Cancer Res. 2008 Apr 1;14(7):2095-101. doi: 10.1158/1078-0432.CCR-07-4024. Clin Cancer Res. 2008. PMID: 18381950 Clinical Trial.
Molecular targets for cancer chemoprevention.
William WN Jr, Heymach JV, Kim ES, Lippman SM. William WN Jr, et al. Nat Rev Drug Discov. 2009 Mar;8(3):213-25. doi: 10.1038/nrd2663. Nat Rev Drug Discov. 2009. PMID: 19247304 Review.
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial.
Kies MS, Holsinger FC, Lee JJ, William WN Jr, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, Byers L, Lippman SM, Hong WK, El-Naggar AK, Garden AS, Papadimitrakopoulou V. Kies MS, et al. Among authors: william wn jr. J Clin Oncol. 2010 Jan 1;28(1):8-14. doi: 10.1200/JCO.2009.23.0425. Epub 2009 Nov 16. J Clin Oncol. 2010. PMID: 19917840 Free PMC article. Clinical Trial.
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.
Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Byers LA, et al. Among authors: william wn. Mol Cancer Ther. 2010 Jun;9(6):1755-63. doi: 10.1158/1535-7163.MCT-09-1047. Epub 2010 Jun 8. Mol Cancer Ther. 2010. PMID: 20530716 Free PMC article.
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, Vaporciyan AA, Wistuba II, Swisher SG; University of Texas M. D. Anderson Lung Cancer Collaborative Research Group. Pataer A, et al. J Thorac Oncol. 2012 May;7(5):825-32. doi: 10.1097/JTO.0b013e318247504a. J Thorac Oncol. 2012. PMID: 22481232 Free PMC article.
Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
William WN Jr, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, Gold KA, Papadimitrakopoulou V, Swisher SG, Erasmus JJ; University of Texas M.D. Anderson Lung Cancer Collaborative Research Group. William WN Jr, et al. J Thorac Oncol. 2013 Feb;8(2):222-8. doi: 10.1097/JTO.0b013e3182774108. J Thorac Oncol. 2013. PMID: 23287849 Free PMC article.
HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
Hah JH, Zhao M, Pickering CR, Frederick MJ, Andrews GA, Jasser SA, Fooshee DR, Milas ZL, Galer C, Sano D, William WN Jr, Kim E, Heymach J, Byers LA, Papadimitrakopoulou V, Myers JN. Hah JH, et al. Among authors: william wn jr. Head Neck. 2014 Nov;36(11):1547-54. doi: 10.1002/hed.23499. Epub 2014 Mar 20. Head Neck. 2014. PMID: 24123531 Free PMC article.
135 results